^
    Apply
    A Study of Avutometinib and Defactinib in People With Thyroid Cancer (NCT06007924)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/16/2023
    Primary completion :
    08/16/2027
    Completion :
    08/16/2027
    BRAF • ALK • RET • NF1 • NTRK
    |
    BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement
    |
    avutometinib (VS-6766) • defactinib (VS-6063)
    A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK) (NCT05512208)
    Phase 2
    University of Oklahoma
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/06/2023
    Primary completion :
    12/01/2027
    Completion :
    12/01/2029
    BRAF • NF1 • RAS
    |
    BRAF mutation • RAS mutation
    |
    avutometinib (VS-6766) • defactinib (VS-6063)
    Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (RAMP 203) (NCT05074810)
    Phase 1/2
    Verastem, Inc.
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    04/12/2022
    Primary completion :
    09/01/2025
    Completion :
    04/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • avutometinib (VS-6766) • defactinib (VS-6063)
    Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE) (NCT06194929)
    Phase 1/2
    University of Utah
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    03/07/2024
    Primary completion :
    01/15/2028
    Completion :
    01/15/2030
    NF1 • RAS
    |
    BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation
    |
    Braftovi (encorafenib) • avutometinib (VS-6766) • defactinib (VS-6063)
    5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (NCT06630260)
    Phase 1/2
    Institute of Cancer Research, United Kingdom
    Recruiting
    Last update posted :
    01/22/2025
    Initiation :
    11/15/2024
    Primary completion :
    09/30/2029
    Completion :
    09/30/2030
    BRAF
    |
    temozolomide • avutometinib (VS-6766) • defactinib (VS-6063)
    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas (A071401) (NCT02523014)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    01/15/2025
    Initiation :
    09/28/2015
    Primary completion :
    01/01/2026
    Completion :
    01/01/2028
    PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3
    |
    PIK3CA mutation • PTEN mutation
    |
    Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098
    Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) (EAY131-U) (NCT04439331)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/08/2024
    Initiation :
    08/12/2015
    Primary completion :
    05/31/2025
    Completion :
    05/31/2025
    NF2
    |
    NF2 mutation
    |
    defactinib (VS-6063)
    a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (NCT06166836)
    Phase 1/2
    InxMed (Shanghai) Co., Ltd.
    Recruiting
    Last update posted :
    01/18/2024
    Initiation :
    10/12/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553) • ifebemtinib (IN10018)
    A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (RAMP-202) (NCT04620330)
    Phase 2
    Verastem, Inc.
    Completed
    Last update posted :
    01/12/2024
    Initiation :
    12/31/2020
    Primary completion :
    08/29/2023
    Completion :
    12/12/2023
    KRAS • BRAF
    |
    KRAS mutation • BRAF mutation • KRAS G12V • KRAS G12
    |
    avutometinib (VS-6766) • defactinib (VS-6063)
    IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (NCT04109456)
    Phase 1
    InxMed (Shanghai) Co., Ltd.
    Recruiting
    Last update posted :
    01/10/2024
    Initiation :
    03/16/2020
    Primary completion :
    06/30/2024
    Completion :
    09/30/2024
    NRAS
    |
    NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib) • ifebemtinib (IN10018)
    APG-2449 in Patients With Advanced Solid Tumors (NCT03917043)
    Phase 1
    Ascentage Pharma Group Inc.
    Recruiting
    Last update posted :
    11/21/2023
    Initiation :
    05/27/2019
    Primary completion :
    01/01/2025
    Completion :
    02/01/2025
    ALK • ROS1
    |
    ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion
    |
    APG-2449
    Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (NCT05379946)
    Phase 1/2
    InventisBio Co., Ltd
    Recruiting
    Last update posted :
    10/18/2023
    Initiation :
    10/12/2022
    Primary completion :
    06/30/2024
    Completion :
    12/30/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    garsorasib (D-1553) • ifebemtinib (IN10018)
    IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (NCT06014528)
    Phase 2
    InxMed (Shanghai) Co., Ltd.
    Recruiting
    Last update posted :
    08/28/2023
    Initiation :
    09/06/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    MUC16
    |
    MUC16 elevation
    |
    pegylated liposomal doxorubicin • ifebemtinib (IN10018)
    Phase I Trial of Defactinib and VS-6766. (FRAME) (NCT03875820)
    Phase 1
    Institute of Cancer Research, United Kingdom
    Active, not recruiting
    Last update posted :
    07/10/2023
    Initiation :
    12/12/2017
    Primary completion :
    04/30/2023
    Completion :
    10/31/2023
    KRAS • RAS
    |
    KRAS mutation • KRAS G12V • RAS mutation • KRAS G12
    |
    avutometinib (VS-6766) • defactinib (VS-6063)
    To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors (NCT01922752)
    Phase 1
    Teva Branded Pharmaceutical Products R&D, Inc.
    Completed
    Last update posted :
    11/12/2021
    Initiation :
    07/01/2013
    Primary completion :
    09/01/2015
    Completion :
    12/01/2015
    ALK
    |
    ALK positive
    |
    CEP-37440
    A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer (NCT01216176)
    Phase 2
    Joyce Marie Slingerland
    Completed
    Last update posted :
    07/31/2019
    Initiation :
    10/21/2008
    Primary completion :
    02/07/2018
    Completion :
    02/07/2018
    HER-2 • ER
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    anastrozole • saracatinib (AZD0530)
    Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer (NCT01951690)
    Phase 2
    Verastem, Inc.
    Completed
    Last update posted :
    04/13/2017
    Initiation :
    09/01/2013
    Primary completion :
    06/01/2016
    Completion :
    06/01/2016
    KRAS • CDKN2A
    |
    KRAS mutation
    |
    defactinib (VS-6063)
    Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer (NCT02695550)
    Phase 1
    Centaurus Biopharma Co., Ltd.
    Unknown status
    Last update posted :
    03/09/2017
    Initiation :
    03/01/2016
    Primary completion :
    03/01/2018
    Completion :
    03/01/2018
    ALK
    |
    ALK positive • ALK rearrangement
    |
    Xalkori (crizotinib) • conteltinib (SY-707)
    A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer (NCT01335269)
    Phase 1
    Boehringer Ingelheim
    Completed
    Last update posted :
    12/09/2015
    Initiation :
    07/01/2011
    Primary completion :
    09/01/2015
    Completion :
    12/01/2015
    CDH1 • PTK2
    |
    CDH1 expression
    |
    ifebemtinib (IN10018)